XML 16 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Changes in Equity - USD ($)
shares in Millions, $ in Millions
Total
Ordinary Shares [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Shares [Member]
Total Teva Shareholders' Equity [Member]
Non-controlling Interests [Member]
Beginning balance at Dec. 31, 2021 $ 11,244 $ 57 $ 27,561 $ (10,529) $ (2,683) $ (4,128) $ 10,278 $ 966
Beginning balance, shares at Dec. 31, 2021   1,209            
Net income (loss) (1,152)     (1,132)     (1,132) (21)
Other comprehensive income (loss) (663)       (470)   (470) (193)
Issuance of Shares, value 1   1       1  
Issuance of Shares, shares   7            
Stock-based compensation expense 88   88       88  
Ending balance at Sep. 30, 2022 9,519 $ 57 27,652 (11,660) (3,153) (4,128) 8,767 751
Ending balance, shares at Sep. 30, 2022   1,216            
Beginning balance at Jun. 30, 2022 9,828 $ 57 27,625 (11,716) (2,801) (4,128) 9,037 791
Beginning balance, shares at Jun. 30, 2022   1,216            
Net income (loss) 58     56     56 3
Other comprehensive income (loss) (395)       (352)   (352) (43)
Stock-based compensation expense 26   26       26  
Ending balance at Sep. 30, 2022 9,519 $ 57 27,652 (11,660) (3,153) (4,128) 8,767 751
Ending balance, shares at Sep. 30, 2022   1,216            
Beginning balance at Dec. 31, 2022 8,691 $ 57 27,688 (12,882) (2,838) (4,128) 7,897 794
Beginning balance, shares at Dec. 31, 2022   1,217            
Net income (loss) (1,048)     (988)     (988) (60)
Other comprehensive income (loss) (156)       (72)   (72) (84)
Issuance of Shares, shares   10            
Stock-based compensation expense 93   93       93  
Dividend to non-controlling interests [1] (67)             (67)
Ending balance at Sep. 30, 2023 7,512 $ 57 27,780 (13,870) (2,910) (4,128) 6,929 582
Ending balance, shares at Sep. 30, 2023   1,227            
Beginning balance at Jun. 30, 2023 7,708 $ 57 27,748 (13,950) (2,677) (4,128) 7,052 656
Beginning balance, shares at Jun. 30, 2023   1,227            
Net income (loss) 88     80     80 8
Other comprehensive income (loss) (249)       (233)   (233) (16)
Stock-based compensation expense 31   31       31  
Dividend to non-controlling interests [1] (67)             (67)
Ending balance at Sep. 30, 2023 $ 7,512 $ 57 $ 27,780 $ (13,870) $ (2,910) $ (4,128) $ 6,929 $ 582
Ending balance, shares at Sep. 30, 2023   1,227            
[1] In connection with a declaration on dividend to
non-controlling
interests in Teva’s joint venture in Japan.